脑出血后检出心房颤动的危险因素与结局
该回顾性队列研究纳入2009至2018年单中心连续收治的532例自发性脑出血并接受持续心电监测的患者,按节律分为窦性心律(参照)、脑出血后检出心房颤动(AFDAS,定义为本次脑出血住院期间检出心房颤动)和已知心房颤动三组。AFDAS发生率为5%,中位检出时间为脑出血住院第3天。AFDAS组住院感染并发症比例高于已知心房颤动组和窦性心律组(67% vs 78%组外32%、窦性心律42%,p=0.01;原文此处写作67% vs 已知心房颤动32%、窦性心律42%,p=0.01)。3个月不良结局(mRS 4-6)在AFDAS组为94%,高于已知心房颤动组78%和窦性心律组65%(p=0.01);校正人口学、脑出血严重度和AFDAS危险因素后,AFDAS与不良结局独立相关(校正OR 11.07,95%CI 1.30-94.27)。作者结论认为AFDAS患者心血管合并症较少但长期结局更差,需进一步前瞻性研究确认。
要点
- 自发性脑出血住院期间持续心电监测检出AFDAS者占5%,中位检出时间为住院第3天。
- AFDAS组3个月不良结局(mRS 4-6)94%,高于已知心房颤动组78%和窦性心律组65%(p=0.01)。
- 校正人口学、脑出血严重度和AFDAS危险因素后,AFDAS与3个月不良结局独立相关(校正OR 11.07,95%CI 1.30-94.27)。
- AFDAS组住院感染并发症67%,高于已知心房颤动组32%和窦性心律组42%(p=0.01)。
- AFDAS患者除高血压患病率较高外,基线心血管合并症少于已知心房颤动患者,超声心动图结构与功能指标与窦性心律患者相似。
适用人群与场景
- 2009至2018年单中心连续收治并纳入的自发性脑出血患者,均接受持续心电监测。
诊断标准与关键阈值
- AFDAS定义:本次脑出血住院期间检出的心房颤动。
- 不良结局定义:3个月随访时改良Rankin量表(mRS)评分4-6分。
研究设计与关键结果
- 研究类型:单中心回顾性队列研究,纳入532例自发性脑出血患者,按节律分为窦性心律(参照)、AFDAS和已知心房颤动三组。
- AFDAS发生率为5%,中位检出时间为脑出血住院第3天。
- 住院感染并发症:AFDAS组67% vs 已知心房颤动组32% vs 窦性心律组42%(p=0.01)。
- 3个月不良结局(mRS 4-6):AFDAS组94% vs 已知心房颤动组78% vs 窦性心律组65%(p=0.01)。
- 多因素logistic回归校正人口学、脑出血严重度和AFDAS危险因素后,AFDAS与不良结局独立相关:校正OR 11.07(95%CI 1.30-94.27)。
- AFDAS患者除高血压患病率较高外,基线心血管合并症少于已知心房颤动患者,超声心动图结构与功能测量与窦性心律患者相似。
- 基线脑出血特征和严重度在各组间相似。
证据类型、等级与局限
- 证据类型:单中心回顾性队列研究。
- 局限:原文未报告局限性。
对床旁实践的改变
- 作者结论认为,脑出血合并AFDAS患者心血管合并症较少但长期结局更差;需进一步前瞻性研究确认这些结果,并明确AFDAS发生的驱动因素及其与脑出血不良结局的联系,以评估AFDAS检测和预防能否改善脑出血。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
BACKGROUND: Atrial fibrillation detected after stroke (AFDAS) refers to newly identified atrial fibrillation occurring after an index cerebrovascular event, most commonly ischemic stroke, but little is known about its occurrence and clinical implications in patients with spontaneous intracerebral hemorrhage (ICH). We aimed to characterize AFDAS risk factors in ICH and AFDAS' relationship with long-term ICH outcomes.
METHODS: We retrospectively analyzed consecutively admitted and enrolled patients with spontaneous ICH to a single tertiary comprehensive stroke center between 2009 and 2018 who underwent continuous cardiac monitoring. Patients were categorized as having sinus rhythm [SR (reference)], atrial fibrillation detected after stroke (AFDAS, defined here as atrial fibrillation (AF) detected during the index ICH hospitalization), and known AF. Demographic, clinical, imaging, and hospitalization complication data were compared across rhythm groups. Poor modified Rankin scale (mRS 4-6) at 3-month follow-up was assessed as the primary clinical outcome. Multivariable logistic regression assessed independent relationships of AFDAS with poor outcomes adjusting for demographics, ICH severity, and AFDAS risk factors.
RESULTS: Amongst 532 patients with ICH, AFDAS occurred in 5% on median ICH hospital day 3. Outside of increased hypertension prevalence, patients with AFDAS had fewer baseline cardiovascular comorbidities compared with patients with known AF yet had similar cardiac risk profiles and structural/function measurements on echocardiogram compared with patients with SR. Baseline ICH characteristics and severity were similar between groups, but patients with AFDAS were more likely to have hospitalization infection complications (67% vs. 32% in known AF, 42% in SR, p = 0.01). Poor 3-month outcome was more common in patients with AFDAS (94%) compared with those with known AF (78%) and sinus rhythm (65%) (p = 0.01), and AFDAS was independently associated with poor outcomes [adjusted odds ratio (OR) 11.07, 95% confidence interval (CI) 1.30-94.27].
CONCLUSIONS: We identified that patients with ICH and AFDAS have less severe cardiovascular comorbidities yet are more likely to have worse long-term outcomes. Further prospective studies are required to confirm these results and characterize drivers for AFDAS development and links between AFDAS and poor ICH outcomes to assess whether AFDAS detection and prevention can improve ICH.
参考来源
- Khasiyev F, Oh K, Velazquez A, et al. Risk Factors and Outcomes Associated with Atrial Fibrillation Detected after Intracerebral Hemorrhage. Neurocrit Care. 2026. PMID: 41845150. doi:10.1007/s12028-026-02479-2
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。